Shamburg News · 8-K filed Nov 6, 2026, 8:30 AM EST
CG Oncology Reports Third Quarter 2026 Financial Results and Business Updates
CGON · CG Oncology, Inc.
- Earnings
- Materiality: high
CG Oncology reported a net loss of $56.9 million, or $(0.64) per share, for the quarter ended September 30, 2026, compared with a net loss of $43.8 million, or $(0.57) per share, a year earlier. Total revenues were $1.6 million for the quarter, and R&D expenses rose to $39.2 million from $27.9 million. Cash, cash equivalents and marketable securities totaled $984.5 million at September 30, 2026, which the company expects to fund operations through 2029.
Source: SEC EDGAR, Form 8-K, Items 2.02, 9.01, accession 0001991792-26-000011.
Written from the filing by Shamburg Markets. Figures are as reported by the company.